Basis of Presentation and Significant Accounting Policies - Narrative (Details)				1 Months Ended					3 Months Ended		12 Months Ended
	May 16, 2024 USD ($)	Mar. 09, 2024 USD ($)	Jan. 29, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2019 USD ($)	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2024 USD ($) segment	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	May 17, 2024 USD ($)	Apr. 30, 2023 USD ($)	Oct. 31, 2018	Sep. 30, 2018
Accumulated deficit									$ 258,788,376		$ 254,370,827
Net loss from continuing operations									(4,657,688)	$ (12,473,000)
Cash, cash equivalents and short term investments												$ 5,600,000
Issuance of common stock from public offering	$ 5,300,000	$ 1,235,000							$ 1,500,000
Number of operating segments | segment									1
Revenue									$ 3,513,948	765,900
Contingent consideration receivable, related party											268,000
Contingent earn-out receivable, related party									2,720,000		$ 1,720,000
Deferred revenue									600,000
Inventory impairment expense									0
Land option agreements									200,000
Shattuck
License fee received								$ 50,000.00
Proceeds from milestone payment				$ 100,000
Shattuck | Kopfkino IP, LLC
Consideration			$ 1,000,000.0
Other income									$ 1,000,000.0
Minimum
Estimated useful lives									3 years
Maximum
Estimated useful lives									8 years
Grant and contract revenue
Amount awarded from NIH grant									$ 8,000	$ 0
Lab equipment
Estimated useful lives									5 years
Computers
Estimated useful lives									3 years
Furniture and fixtures and vehicles
Estimated useful lives									8 years
Pelican Therapeutics, Inc.
Ownership interest in subsidiary									85.00%					85.00%	80.00%
Scorpius Therapeutics, Inc.
Ownership interest in subsidiary											94.00%
Pelican Therapeutics, Inc. | Grant and contract revenue
Amount awarded from CPRIT grant											$ 15,200,000
Remaining grant amount receivable													$ 1,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 1
Revenue							$ 1,800,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 2
Revenue						$ 6,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 3
Revenue					$ 5,400,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Maximum
Amount awarded from CPRIT grant								$ 15,200,000